A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Trial Profile

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2018

At a glance

  • Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Lenalidomide; Sargramostim
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 May 2018 Planned End Date changed from 9 Nov 2019 to 9 Nov 2023.
    • 03 May 2018 Planned primary completion date changed from 9 Nov 2018 to 9 Nov 2022.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top